stockrow
Friday 6 November 2026
Export MBX’s income statement to Excel — free account
MBX Biosciences, Inc.
- EPS
- −34.5%
- Free cash flow
- −29.7%
Quarter to June 2026, against a year earlier
50.96
2.50
+5.16%
Follow MBX
Alert me
MBX Biosciences, Inc. (MBX) Debt to equity
MBX Biosciences, Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 0.0×, down 0.0× from fiscal 2025 (0.0×). That is in line with the Biotechnology industry median of 0.0× and in line with the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 8 more quarters | Free account |
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| NAMS NewAmsterdam Pharma Company N.V. compare | 0.0× |
| MBX MBX Biosciences, Inc. | 0.0× |
| ADMA ADMA Biologics Inc compare | 0.0× |
| XNCR Xencor, Inc. compare | 0.0× |
| RXRX Recursion Pharmaceuticals, Inc. compare | 0.0× |
| PHVS Pharvaris N.V. compare | 0.0× |
| CLDX Celldex Therapeutics, Inc. compare | 0.0× |
| RCUS Arcus Biosciences, Inc. compare | 0.3× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 0.4× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)